COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #149 of 231
10/6 Late treatment study
Ader et al., medRxiv, doi:10.1101/2021.01.08.20248149 (news 10/6) (Preprint)
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Source   PDF   Share   Tweet
Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial. 4% more patients were on ventilation at baseline in the HCQ group.


Ader et al., 10/6/2020, Randomized Controlled Trial, multiple countries, Europe, preprint, baseline oxygen requirements 95.4%, 52 authors.
risk of death at day 29, 6.4% lower, RR 0.94, p = 1.00, treatment 11 of 145 (7.6%), control 12 of 148 (8.1%).
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit